Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update


Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL

Go here to read the rest:
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Related Posts